M2 PHARMA-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis
biosimilar natalizumab
M2 EQUITYBITES-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis
biosimilar natalizumab
Global Banking News-September 3, 2019-Polpharma Biologics signs global commercialisation agreement for
biosimilar Natalizumab for MS
Fact.MR has announced the addition of the "Pegfilgrastim
Biosimilar Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028"report to their offering.
Coherus BioSciences is a leading
biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.
As prescription drug costs continue to increase,
biosimilar medicines represent hope for patients seeking access to more affordable treatment.
M2 PRESSWIRE-July 29, 2019-:
Biosimilar Market Trends Report 2019: EU Guidelines, US Guidelines, Interchangeability, Patent and Patent Dance Issues
Amgen (AMGN) and Allergan (AGN) announced that Mvasi, a
biosimilar to Avastin, and Kanjinti, a
biosimilar to Herceptin, are now available in the United States.
(Alliance News) - US biopharmaceutical firm Amgen Inc said Thursday two of its
biosimilar cancer treatments are now available in the US.
The agreement covers multiple
biosimilar candidates from Samsung Bioepis, including third-wave
biosimilar candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a
biosimilar candidate referencing Herceptin 3 (trastuzumab).